Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • The Rise of Micromobility Among Younger Consumers

    Led by Gen Z, micromobility is gaining momentum, but availability and safety remain major hurdles.

    Read more

  • Cautious Optimism for IT Spending in 2026

    As IT budgets stabilize, AI-led modernization is unlocking new opportunities for service providers and investors in 2026.

    Read more

  • Replay: Macro Perspectives from William Blair’s 46th Annual Growth Stock Conference

    During the 46th annual Growth Stock Conference, William Blair macro analyst Richard de Chazal examined a changing macro backdrop, highlighting a shift toward a more structurally inflationary environment.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures